比较接受促性腺激素释放激素 (GnRH) 拮抗剂、地加瑞克和 GnRH 激动剂治疗的患者之间的睾酮去势水平。单个门诊诊所的前列腺癌 (PCa) 患者被随机 (2:1) 接受地加瑞克治疗（A 组） ) 或 GnRH 激动剂（B 组）。该研究评估了睾酮和前列腺特异性抗原（PSA）水平、患者年龄、格里森评分以及是否存在转移（淋巴结或骨）。在第 1、6、12 和 18 个月测量睾酮和 PSA 水平。曼-惠特尼检验和斯皮尔曼相关用于研究自变量，而标准多元回归则用于探索统计上显着的相关性。采用 Kruskal-Wallis 检验比较随访时的睾酮水平。该研究纳入了 168 名患者，其中 A 组 107 例，B 组 61 例。接受 GnRH 拮抗剂治疗的患者第 1 个月的睾酮水平显着低于接受 GnRH 激动剂治疗的患者。 A 组：22 ng/dL 对比 B 组：29 ng/dL，p=0.011）。然而，PSA 值在各组之间没有显着差异（A 组：0.130 ng/mL vs. B 组：0.067 ng/mL，p=0.261）。在多变量分析中，地加瑞克治疗是第 1 个月睾酮水平较低的独立因素 (p=0.013)。比较 6、12 和 18 个月时的睾酮水平，未发现各组内有任何显着差异。在适合雄激素剥夺治疗的 PCa 患者中，与 GnRH 拮抗剂治疗相比，给予 GnRH 拮抗剂似乎可显着降低睾酮水平。治疗第 1 个月使用 GnRH 激动剂。© 韩国泌尿外科协会。

To compare testosterone castration levels between patients treated with the gonadotropin-releasing hormone (GnRH) antagonist, degarelix, and GnRH agonist.Patients with prostate cancer (PCa) of a single outpatient clinic were randomized (2:1) to receive degarelix (group A) or GnRH agonist (group B). The study evaluated testosterone and prostate-specific antigen (PSA) levels, patients' age, Gleason score and the presence of metastases (nodal or bone). Testosterone and PSA levels were measured at 1st, 6th, 12th, and 18th months. Mann-Whitney test and Spearman correlation were used to investigate independent variable while standard multiple regression was performed to explore statistically significant correlations. Kruskal-Wallis test was used to compare testosterone levels at follow-up.The study included 168 patients, 107 in group A and 61 in group B. Testosterone levels at 1st month were significantly lower in patients under GnRH antagonist than those receiving GnRH agonist (group A: 22 ng/dL vs. group B: 29 ng/dL, p=0.011). However, PSA values did not differ significantly between groups (group A: 0.130 ng/mL vs. group B: 0.067 ng/mL, p=0.261). In multivariate analysis, treatment with degarelix was an independent factor of lower testosterone levels at 1st month (p=0.013). Comparison of testosterone levels at 6, 12, and 18 months did not reveal any significant difference within each group.In patients with PCa who are candidates for androgen deprivation therapy, the administration of GnRH antagonist seems to achieve significantly lower testosterone levels compared to treatment with GnRH agonist at 1st month of treatment.© The Korean Urological Association.